₹ 49.80
-0.44 (-0.88%)Open
50.36High
50.66Low
49.34Prev Close
50.24P/E
33.33Median P/E
31.46P/B
3.42Median P/B
4.43Market Cap
25.46BPEG
0.41Div.Yield
-Bid
-Ask
-Large Cap
25.46B Mkt. Cap.Volatility
-Beta
1.5Genie Says
Influencer Count
-Days | BSE | NSE |
---|
5 | 50.47 | 50.52 |
10 | 48.19 | 48.21 |
20 | 46.97 | 47.01 |
50 | 47.50 | 47.51 |
100 | 47.74 | 47.75 |
300 | 41.77 | 41.77 |
BSE
500288NSE
MOREPENLABISIN
INE083A01026Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Sushil Suri
Executive Chairman of the Board, Managing DirectorAjay Sharma
Chief Financial OfficerVipul Srivatava
Compliance Officer, Company SecretarySanjay Suri
Whole-Time Director